Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression (Q34155693)

31 July 2017

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression (English)

1 reference

31 July 2017

0 references

Michael J Detke

1

1 reference

31 July 2017

Yili Lu

2

1 reference

31 July 2017

David J Goldstein

3

1 reference

31 July 2017

Robert K McNamara

4

1 reference

31 July 2017

Mark A Demitrack

5

1 reference

31 July 2017

1 November 2002

1 reference

Journal of Psychiatric Research

31 July 2017

1 reference

31 July 2017

36

1 reference

31 July 2017

6

1 reference

31 July 2017

383-390

1 reference

The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

A systematic review of the associations between dose regimens and medication compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

The QLDS: a scale for the measurement of quality of life in depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Symptoms in the community. Prevalence, classification, and psychiatric comorbidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

The role of the primary care physician in patients' adherence to antidepressant therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Accounting for dropout bias using mixed-effects models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Type I Error Rates from Mixed Effects Model Repeated Measures versus Fixed Effects Anova with Missing Values Imputed via Last Observation Carried Forward

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Serotonin and nociception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Treatment of acute depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

An international study of the relation between somatic symptoms and depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Neuroanatomy of the pain system and of the pathways that modulate pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Administration of antidepressants. Single versus split dosing: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Characterization of descending facilitation and inhibition of spinal nociceptive transmission from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

Descending noradrenergic influences on pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900060-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3956(02)00060-2

1 reference

release_4tkkds4mmzgnpbv6dtr3cneebm

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4tkkds4mmzgnpbv6dtr3cneebm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference